Jill Feldman: Lay summaries on some of the top research presented at ASCO24

Jill Feldman shared on X/Twitter:

“Here are lay summaries on some of the top research presented at ASCO24.

Each summary includes:

• Who does this study affect?
• What did this study find?
• What does this mean for patients?

Thank you, ASCO, for your efforts to help the lay community understand all the exciting research from the conference!”

Source: Jill Feldman/X

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board.

Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.